Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Fatemeh Barazandeh Ahmadabadi"'
Autor:
Daryoush Hamidi-Alamdari, Amin Ghiabi, Mahnaz Amini, George Koliakos, Seyed M. Tavousi, Abass Ali-Zeraati, Ahmad Bagheri-Moghaddam, Mahnaz Mozdourian, Ashraf Tavanaee-Sani, Hossin Safari, Shohreh Vojouhi, Fatemeh Barazandeh-Ahmadabadi, Marzieh Agheli-Rad, Saied Hafizi-Lotfabadi, Shahram Amini, Arash Peivandi-Yazdi, Farid Poursadegh, Alireza Sedaghat, Zahra Javidarabshahi, Negar Morovatdar, Shima Nabavi-Mahalli, Omid Rajabi, Seyed Majid-Hosseini
Publikováno v:
Revista de investigaci�n Cl�nica. 73
Background: There is no pharmacological intervention on the treatment of hypoxemia and respiratory distress in COVID-19 patients. Objective: The objective of the study was to study the effect of the reduced form of methylene blue (MB) on the improvem
Publikováno v:
Archives of Clinical Infectious Diseases. 13
Introduction: The term hepatobiliary tuberculosis refers to the rare and localized form of hepatic tuberculosis as a distinct clinical entity, with signs and symptoms related to the hepatobiliary tract. We aimed to report a case of the primary biliar
Publikováno v:
Australasian Journal of Dermatology. 57:e1-e4
Introduction Hirsutism is defined as the excessive male-pattern growth of hair in women. Hirsutism is often idiopathic or the consequence of polycystic ovary syndrome (PCOS). Insulin resistance is common in PCOS (especially in obese patients) but the
Autor:
Daryoush Hamidi Alamdari, Saied Hafizi Lotfabadi, Behzad Mavaji Darban, Marzieh Agheli-Rad, Shahin Saadatian, Seyed Hadi Hashemi, Fatemeh Barazandeh Ahmadabadi, Negar Morovatdar, Mohammad Arastoo, Bharat Bhushan
Publikováno v:
University of Aberdeen-PURE
Background: Methylene blue (MB) possesses all the required properties for the clinical management of COVID-19. We have coined methylene blue as an anti-hypoxemia and anti-respiratory distress agent and previously witnessed promising results in phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b1656466b6f8c03146bcdf11b1bee8
https://abdn.pure.elsevier.com/en/en/researchoutput/methylene-blue-for-treatment-of-hospitalized-covid19-patients-randomized-controlled-openlabel-clinical-trial-phase-3(61565c11-e3b0-4e62-8cbd-80d484f723ba).html
https://abdn.pure.elsevier.com/en/en/researchoutput/methylene-blue-for-treatment-of-hospitalized-covid19-patients-randomized-controlled-openlabel-clinical-trial-phase-3(61565c11-e3b0-4e62-8cbd-80d484f723ba).html